Abstract 207P
Background
Diabetes mellitus is considered as a potential risk factor for breast cancer, yet the relationship between diabetic background retinopathy (DBR) and breast cancer remains uncertain. This study leverages mendelian randomization (MR) to explore the genetic link between diabetic background retinopathy (DBR) and estrogen receptor-positive (ER+) breast cancer, highlighting the connection with diabetes-related conditions.
Methods
We acquired summary data from a genome-wide association study (GWAS) concerning DBR in the European population, with a focus on their relationship with ER+ breast cancer. We performed two-sample MR analysis with multiple approaches to evaluate the potential causal associations between DBR and ER+ breast cancer. Pleiotropy and Cochran's Q tests were utilized to determine horizontal pleiotropy and heterogeneity.
Results
Of the 205,044 participants (2,026 DBR cases) from FinnGenn, we identified 8 single nucleotide polymorphisms (SNPs) associated with the risk of ER+ breast cancer (69,501 ER+ breast cancer cases from iCOGS). The MR analysis showed a suggestive association between DBR susceptibility and ER+ breast cancer (weight median odds ratio [OR]: 0.971, 95% confidence interval [CI]: 0.955-0.987, P = 0.0006; simple mode OR: 0.964, P = 0.043; weight mode OR: 0.971, P = 0.015). The effect size estimate (β) for weight median model was -0.0294, indicating a 2.94% decrease in the odds of ER+ breast cancer per unit increase in genetically predicted DBR. Sensitivity analyses are consistent with the results, manifesting that our findings were convincing and robust.
Conclusions
These finding suggests that a potential inverse relationship between DBR and the risk of ER+ breast cancer. These findings could significantly impact screening and prevention strategies for diabetic populations, emphasizing the need for further research into this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
826P - Efficacy of non-doxorubicin based regimens in severely G6PD deficient patients with DLBCL
Presenter: Shruti Prem Sudha
Session: Poster session 09
827P - Comparison of efficacy and safety between glofitamab and real-world regimens among Chinese patients with 3L+ relapsed/refractory diffuse large B-cell lymphoma: An external control study
Presenter: Keshu Zhou
Session: Poster session 09
828P - Translocation 11;14 is not associated with adverse prognosis in the era of novel anti-myeloma therapeutics
Presenter: Ioannis Ntanasis-Stathopoulos
Session: Poster session 09
829P - Flumatinib combined with chemotherapy for newly diagnosed adult with Ph-positive acute lymphoblastic leukemia: A single-center, retrospective observational study
Presenter: HAN SHUYU
Session: Poster session 09
830P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Poster session 09
Resources:
Abstract
831P - Impact of chronic kidney disease on disease outcomes in hospitalized multiple myeloma patients: A National inpatient sample study from 2016 to 2020
Presenter: Marco Bermudez
Session: Poster session 09
Resources:
Abstract
832P - CLOMB: A validated scoring model to predict the relapse in the central nervous system of pediatric acute B-cell lymphoblastic leukemia
Presenter: Jiacheng Li
Session: Poster session 09
Resources:
Abstract
833P - Latest results of GVM±R regimen for the salvage therapy of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Presenter: Wei Liu
Session: Poster session 09
834P - Treatment of DLBCL in HIV patient: Still a dilemma
Presenter: Devashish Desai
Session: Poster session 09
835P - Genetic, epigenetic, and clinical significance of Wilms’ tumor 1 (WT1) gene in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract